{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T18:40:56Z","timestamp":1768675256168,"version":"3.49.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,6,30]],"date-time":"2015-06-30T00:00:00Z","timestamp":1435622400000},"content-version":"vor","delay-in-days":637,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"University of Texas M.D. Anderson Cancer Center"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.bbmt.2013.07.008","type":"journal-article","created":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T23:47:14Z","timestamp":1374018434000},"page":"1453-1458","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["A Randomized Phase II Trial of Fludarabine\/Melphalan 100 versus Fludarabine\/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma"],"prefix":"10.1016","volume":"19","author":[{"given":"Qaiser","family":"Bashir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter F.","family":"Thall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simrit","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Betul","family":"Oran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yago","family":"Nieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chitra M.","family":"Hosing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uday R.","family":"Popat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne T.","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Rondon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jatin J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"De Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Shpall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muzaffar H.","family":"Qazilbash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2013.07.008_bib1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.beha.2007.09.007","article-title":"Is there still a role for allogeneic stem-cell transplantation in multiple myeloma?","volume":"20","author":"Bensinger","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.bbmt.2013.07.008_bib2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.bmt.1703253","article-title":"Allogeneic transplantation for multiple myeloma: Further evidence for a GVHD-associated graft-versus-myeloma effect","volume":"28","author":"Le Blanc","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.07.008_bib3","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.07.008_bib4","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3324\/haematol.11353","article-title":"Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma","volume":"92","author":"Gahrton","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2013.07.008_bib5","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2002-01-0131","article-title":"Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma","volume":"100","author":"Kroger","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.07.008_bib6","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.07.008_bib7","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1182\/blood.V89.12.4531","article-title":"Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy","volume":"89","author":"Giralt","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.07.008_bib8","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","article-title":"Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies","volume":"16","author":"Khouri","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.07.008_bib9","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.bbmt.2010.02.015","article-title":"Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma","volume":"16","author":"Efebera","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.07.008_bib10","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1182\/blood.V97.9.2574","article-title":"High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions","volume":"97","author":"Badros","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.07.008_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1046\/j.1365-2141.1999.01685.x","article-title":"High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma","volume":"107","author":"Almeida","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2013.07.008_bib12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/sj.bmt.1705425","article-title":"Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia","volume":"38","author":"Kebriaei","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.07.008_bib13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1083-8791(03)00216-7","article-title":"Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody","volume":"9","author":"Ratanatharathorn","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.07.008_bib14","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2005-06-2462","article-title":"Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: A report from the European Group for Blood and Marrow Transplantation","volume":"107","author":"Schonland","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.07.008_bib15","first-page":"1698","article-title":"Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow","volume":"83","author":"Selvaggi","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.07.008_bib16","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3109\/10428194.2010.501534","article-title":"Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy","volume":"51","author":"Bashir","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2013.07.008_bib17","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/sj.bmt.1701983","article-title":"Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation","volume":"24","author":"Przepiorka","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.07.008_bib18","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once-daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.07.008_bib19","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1182\/blood-2009-05-223172","article-title":"Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease","volume":"114","author":"Parmar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.07.008_bib20","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2013.07.008_bib21","doi-asserted-by":"crossref","first-page":"532","DOI":"10.4065\/mcp.2009.0677","article-title":"Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapies","volume":"85","author":"Kapoor","year":"2010","journal-title":"Mayo Clinic Proc"},{"key":"10.1016\/j.bbmt.2013.07.008_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2307\/2529712","article-title":"Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial","volume":"31","author":"Pocock","year":"1975","journal-title":"Biometrics"},{"key":"10.1016\/j.bbmt.2013.07.008_bib23","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1002\/(SICI)1097-0258(19980730)17:14<1563::AID-SIM873>3.0.CO;2-L","article-title":"Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials","volume":"17","author":"Thall","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.bbmt.2013.07.008_bib24","series-title":"Applied Logistic Regression","author":"Hosmer","year":"2000"},{"key":"10.1016\/j.bbmt.2013.07.008_bib25","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2307\/2340521","article-title":"On the interpretation of x2 from contingency tables, and the calculation of P","volume":"85","author":"Fischer","year":"1922","journal-title":"J\u00a0Royal Stat Soc"},{"key":"10.1016\/j.bbmt.2013.07.008_bib26","series-title":"Introduction to the Theory of Nonparametric Statistics","author":"Randles","year":"1979"},{"key":"10.1016\/j.bbmt.2013.07.008_bib27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2013.07.008_bib28","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"10.1016\/j.bbmt.2013.07.008_bib29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables (with discussion)","volume":"34","author":"Cox","year":"1972","journal-title":"J\u00a0Royal Stat Soc Series B"},{"key":"10.1016\/j.bbmt.2013.07.008_bib30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"10.1016\/j.bbmt.2013.07.008_bib31","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2013.07.008_bib32","first-page":"479","article-title":"Treatment of multiple myeloma. Nature reviews","volume":"8","author":"Rajkumar","year":"2011","journal-title":"Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.07.008_bib33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0301-472X(02)01010-X","article-title":"Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning","volume":"31","author":"Lee","year":"2003","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2013.07.008_bib34","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ajh.22273","article-title":"Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma","volume":"87","author":"Bashir","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2013.07.008_bib35","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A\u00a0comparison of allografting with autografting for newly diagnosed myeloma","volume":"356","author":"Bruno","year":"2007","journal-title":"N\u00a0England J Med"},{"key":"10.1016\/j.bbmt.2013.07.008_bib36","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2010.32.7312","article-title":"Tandem autologous\/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: Long-term follow-up","volume":"29","author":"Bjorkstrand","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.07.008_bib37","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","article-title":"A\u00a0prospective PETHEMA\u00a0study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma","volume":"112","author":"Rosinol","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.07.008_bib38","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): A phase 3 biological assignment trial","volume":"12","author":"Krishnan","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2013.07.008_bib39","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1182\/blood-2011-11-393801","article-title":"Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study","volume":"119","author":"Lokhorst","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.07.008_bib40","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.07.008_bib41","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bbmt.2011.10.044","article-title":"Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival","volume":"18","author":"Jimenez-Zepeda","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.07.008_bib42","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.bbmt.2013.01.004","article-title":"Salvage second hematopoietic cell transplantation in myeloma","volume":"19","author":"Michaelis","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.07.008_bib43","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/sj.bmt.1701208","article-title":"Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?","volume":"21","author":"Mehta","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.07.008_bib44","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/bmt.2012.1","article-title":"Allo-SCT for multiple myeloma: A\u00a0review of outcomes at a single transplant center","volume":"47","author":"Bensinger","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.07.008_bib45","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/bmt.2011.192","article-title":"Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma","volume":"47","author":"Ringden","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.07.008_bib46","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.bbmt.2004.06.002","article-title":"Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan\/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma","volume":"10","author":"Kroger","year":"2004","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2013.07.008_bib47","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/leu.2008.88","article-title":"Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma","volume":"22","author":"Schilling","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2013.07.008_bib48","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A\u00a0validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.07.008_bib49","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N\u00a0England J Med"},{"key":"10.1016\/j.bbmt.2013.07.008_bib50","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1200\/JCO.2010.28.3945","article-title":"Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)","volume":"28","author":"Avet-Loiseau","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2013.07.008_bib51","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1182\/blood-2011-04-345801","article-title":"Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance","volume":"118","author":"Mateos","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.07.008_bib52","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3324\/haematol.12665","article-title":"Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation","volume":"93","author":"Ayuk","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2013.07.008_bib53","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2009.07984.x","article-title":"Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation","volume":"148","author":"Kroger","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2013.07.008_bib54","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.51.51","article-title":"Allogeneic stem cell transplant versus tandem high-dose melphalan for front-line treatment of deletion 13q14 myeloma \u2013 an interim analysis of the German DSMM V trial","volume":"114","author":"Knop","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2013.07.008_bib55","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.3109\/10428194.2011.582201","article-title":"Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: Factors associated with improved survival outcome","volume":"52","author":"Nivison-Smith","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2013.07.008_bib56","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1002\/cncr.25228","article-title":"Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: Long-term follow-up","volume":"116","author":"Shimoni","year":"2010","journal-title":"Cancer"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879113003029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879113003029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:45:33Z","timestamp":1761057933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879113003029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S1083879113003029"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2013.07.008","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized Phase II Trial of Fludarabine\/Melphalan 100 versus Fludarabine\/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2013.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}